Cryptococcosis Clinical Presentation
- Author: John W King, MD; Chief Editor: Pranatharthi Haran Chandrasekar, MBBS, MD more...
The principal site or sites of infection (ie, pulmonary, CNS, disseminated disease) dictate the medical history of patients with symptomatic cryptococcal disease. Factors that are especially important include the presence of coexisting conditions associated with immunosuppression (eg, steroid use, malignant disease, transplantation) or HIV infection. Other key factors in the history often relate to organ-specific problems (eg, cough, headaches, focal neurological defects, skin rashes).
Cryptococcus has become an increasingly common infection among patients who have received solid organ transplants and is now among the 3 most common invasive fungal infections in the posttransplant period. Cryptococcus infections in solid organ transplant recipients usually occur 1-2 years after transplantation. However, a study identified a subset of patients who developed invasive cryptococcal disease within the first 30 days. In 2 patients, invasive cryptococcal disease occurred in the first posttransplant day. The source of these infections are most likely unrecognized pretransplant infections or donor-derived infections. Most of the patients in this report were liver transplant recipients.
The pattern of cryptococcal pulmonary disease varies greatly, ranging from asymptomatic saprophytic airway colonization to acute respiratory distress syndrome, which affects immunocompromised hosts (eg, patients with AIDS, organ transplant recipients). On occasion, cryptococcal pulmonary disease may even manifest as a slowly progressive mass that may compress thoracic structures such as the vena cava.
A patient with pulmonary cryptococcosis may present with mild-to-moderate symptoms, including fever, malaise, cough with scant sputum, pleuritic pain, and hemoptysis (rare). Unusual findings include rales or pleural rub. Pleural effusions may be present but are uncommon.
Cavitation and hilar lymphadenopathy are uncommon.
Calcification and pulmonary fibrosis or stranding are usually absent.
Although chronic infection can occur, immunocompetent patients usually have spontaneous regression of both clinical and radiological manifestations.
Among patients who are HIV positive and have a pulmonary cryptococcal infection, 5%-25% present with cough and dyspnea.
Adult respiratory distress syndrome may ensue.
Pulmonary disease is more likely to progress in immunocompromised patients and to require antifungal therapy.
Pulmonary disease may occur in the absence of extrapulmonary disease. Conversely, extrapulmonary disease (eg, meningitis) may develop in the absence of identifiable pulmonary pathology.
Meningitis and meningoencephalitis are the most common manifestations of CNS cryptococcosis and are usually subacute or chronic in nature.
This form of infection is invariably fatal without appropriate therapy; death may occur from 2 weeks to several years after symptom onset.
The clinical presentation and course of cryptococcal meningitis vary, relating in part to underlying medical conditions (eg, diabetes, sarcoidosis, glucocorticoid use) and the immune status of the host.
The most common symptoms are headache and altered mental status, including personality changes, confusion, lethargy, obtundation, and coma.
Nausea and vomiting are common and are often associated with increased intracranial pressure, whereas fever and stiff neck, symptoms associated with a more aggressive inflammatory response, are less common.
Some patients who are HIV positive may have minimal or nonspecific symptoms at presentation. Patients are often afebrile or have a mildly elevated temperature.
Other findings include hearing defects, seizures, ataxia, aphasia, and choreoathetoid movements.
Dementia is a potential sequela and may indicate the presence of hydrocephalus as a late complication.
Cryptococcosis in other sites
After lung and CNS infection, the next most commonly involved organs in disseminated cryptococcosis include the skin, prostate, and the medullary cavity of bones.
Cutaneous manifestations occur in 10%-15% of cases and usually take the form of papules, pustules, nodules, ulcers, or draining sinuses.
Umbilicated papules in patients with AIDS may resemble molluscum contagiosum.
Cellulitis with necrotizing vasculitis is reported in patients who undergo organ transplantation.
Bone lesions develop in 5%-10% of patients and are usually osteolytic or resemble cold abscesses. These lesions may be confused with tuberculosis or neoplasm.
Other less common forms of cryptococcosis include the following:
Prostatitis (Prostatic foci of cryptococci may persist after therapy for CNS disease and may act as a reservoir for relapse in men with AIDS.)
The physical findings of patients with cryptococcal infection primarily depend on the patient’s immune status prior to infection and the site or sites involved. Because the inflammatory responses to encapsulated cryptococci are blunted, tissues may be extensively involved before the patient presents for medical care. Furthermore, the limited inflammatory response associated with the encapsulated yeast can result in mild clinical findings, further complicating diagnosis.
Although C neoformans most often infects patients via the pulmonary route, less than 15% of patients present with a clinical picture of pneumonia. On occasion, isolation of Cryptococcus from sputum may represent colonization rather than true infection, especially in patients with chronic obstructive pulmonary disease (COPD) or bronchiectasis.
One third of immunocompetent patients who develop pulmonary infection are asymptomatic or have symptoms so mild that they do not seek medical care.
When symptoms develop in immunocompetent hosts, they include cough (54%), cough with the production of scant mucoid sputum (32%), and pleuritic chest pain (46%). Low-grade fever, dyspnea, weight loss, and malaise may also be present.
Night sweats, as observed in tuberculosis, are uncommon in cryptococcal pulmonary disease but may occur with disseminated or CNS disease.
In immunocompromised patients who do not have HIV infection, cryptococcal pulmonary infection is associated with an accelerated course, often with early dissemination. As many as 83% of these patients present with constitutional symptoms (eg, fever, malaise).
Patients co-infected with HIV and Cryptococcus present with fever (84%), cough (63%), dyspnea (50%), headache (41%), and weight loss (47%). Often, patients with co-infection have cryptococcal antigens and cultures that are positive in cerebrospinal fluid (CSF), blood, and urine. Any part of a lung may be involved, and infiltrates may be bilateral, unilateral, multilobar, or lobar.
Although C neoformans enters the body via the lungs, the CNS is the main site of clinically evident infection in both immunocompetent and immunocompromised hosts. Following pulmonary infection, cryptococci disseminate widely and may infect any organ. The organs most often involved include the CNS, bones, prostate, eyes, and skin. Prior to the discovery of amphotericin B in 1955, 80% of patients with CNS involvement died within 2 years of diagnosis.
Cryptococcal CNS infections usually involve both the brain and meninges, causing diffuse disease. Immunocompetent hosts may present with either meningitis or focal cryptococcomas. Meningitis manifests with diffuse nonfocal findings (eg, altered mental status, vomiting), whereas cryptococcomas often manifest with focal neurologic defects.
Cryptococcal skin infection
Approximately 10%-15% of patients infected with C neoformans develop skin involvement. In immunocompetent hosts, the skin may be the only site of infection; however, immunosuppressed patients, especially those with AIDS, have skin involvement that must be considered evidence of disseminated disease.
Cutaneous lesions include nodules, ulcers, papules, and vasculitic lesions.
Bone involvement is documented in 5%-10% of patients with cryptococcal infection.
Bone lesions are usually osteolytic and may be misinterpreted as neoplastic lesions or osseous tuberculosis.
Other sites of cryptococcal infection
The eyes and prostate are often involved. Eye involvement often manifests as vision loss caused by optic neuritis or endophthalmitis. Rapid diagnosis and treatment are essential to preserve the patient's sight.
In men, eradication of cryptococci from the prostate is often difficult, and prostatic foci of infection can act as a reservoir for relapse of systemic infections.
A CT scan or MRI in patients with cryptococcal infection may reveal diffuse atrophy or cerebral edema with focal, homogenous, or contrast-enhanced areas. These findings may help distinguish cryptococcal infection from other causes of intracranial mass lesions and infections. However, scans are not diagnostic in and of themselves.
Early cryptococcal meningitis may resemble other mycoses, syphilis, tuberculosis, or meningeal metastases. Do not confuse this condition with chronic meningitis caused by other infections or by noninfectious causes (eg, sarcoidosis, chronic benign lymphocytic meningitis).
Pulmonary findings may be indistinguishable from those in patients with acute pneumonia caused by Pneumocystis jiroveci (previously Pneumocystiscarinii), Mycobacterium tuberculous, Histoplasma capsulatum, or other organisms.
Cutaneous lesions are nonspecific and may be mistaken for a large variety of lesions related to other causes, including acne, syphilis, lipoma, tuberculosis, molluscum contagiosum, or basal cell carcinoma.
Bone lesions may be mistaken for tubercular cold abscess or neoplasm.
Infection with either C neoformans or Cgattii causes cryptococcal disease. The most common pathogen of the genus Cryptococcus in immunocompromised patients is C neoformans. Both C neoformans and Cgattii cause disease in immunocompetent patients. Most patients with disease due to C gattii have been reported to be immunocompetent.
[Guideline] Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis. 2000 Apr. 30(4):710-8. [Medline].
[Guideline] Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep. 2002 Jun 14. 51:1-52. [Medline].
[Guideline] Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010 Feb 1. 50 (3):291-322. [Medline].
Busse O. Ueber parasitare zelleninschlusse und ihre zuchtung. Zentralbl. Bakterial. 1894. 16:175-80.
Buschke A. Ueber eine durch Coccidien Hervergerufene Krankheit des menschen. Deutsche Med. Wochenschr. 1895. 21 (3):14.
Macdougall L, Fyfe M, Romney M, Starr M, Galanis E. Risk Factors for Cryptococcus gattii Infection, British Columbia, Canada. Emerg Infect Dis. 2011 Feb. 17(2):193-9. [Medline].
Rittershaus PC, Kechichian TB, Allegood JC, Merrill AH Jr, Hennig M, Luberto C. Glucosylceramide synthase is an essential regulator of pathogenicity of Cryptococcus neoformans. J Clin Invest. 2006 Jun. 116(6):1651-9. [Medline]. [Full Text].
Beardsley J, Wolbers M, Kibengo FM, et al. Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis. N Engl J Med. 2016 Feb 11. 374 (6):542-54. [Medline].
Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin Infect Dis. 1995 Jul. 21(1):28-34; discussion 35-6. [Medline].
Lewis JL, Rabinovich S. The wide spectrum of cryptococcal infections. Am J Med. 1972 Sep. 53(3):315-22. [Medline].
Sun HY, Alexander BD, Lortholary O, et al. Unrecognized pretransplant and donor-derived cryptococcal disease in organ transplant recipients. Clin Infect Dis. 2010 Nov 1. 51(9):1062-9. [Medline].
Lindsley MD, Mekha N, Baggett HC, Surinthong Y, Autthateinchai R, Sawatwong P, et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis. 2011 Aug. 53(4):321-5. [Medline]. [Full Text].
Pappas PG, Perfect J, Larsen RA, et al. Cryptococcus in HIV-negative patients: analysis of 306 cases [abstract 101]. 36th Annual Meeting of the Infectious Diseases Society of America (Denver, CO). Alexandria, VA: Infectious Diseases Society of America; 1998.
Lortholary O, Fontanet A, Mémain N, Martin A, Sitbon K, Dromer F. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS. 2005 Jul 1. 19(10):1043-9. [Medline].
Sungkanuparph S, Filler SG, Chetchotisakd P, Pappas PG, Nolen TL, Manosuthi W, et al. Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. Clin Infect Dis. 2009 Sep 15. 49(6):931-4. [Medline].
Bisson GP, Molefi M, Bellamy S, Thakur R, Steenhoff A, Tamuhla N, et al. Early Versus Delayed Antiretroviral Therapy and Cerebrospinal Fluid Fungal Clearance in Adults With HIV and Cryptococcal Meningitis. Clin Infect Dis. 2013 Feb 6. [Medline].
Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ. 2001 Mar 10. 322(7286):579-82. [Medline]. [Full Text].
Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis. 2003 Apr 15. 36(8):943-51. [Medline].
Anderson DJ, Schmidt C, Goodman J, Pomeroy C. Cryptococcal disease presenting as cellulitis. Clin Infect Dis. 1992 Mar. 14(3):666-72. [Medline].
Baddley JW, Perfect JR, Oster RA, Larsen RA, Pankey GA, Henderson H, et al. Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis. 2008 Oct. 27(10):937-43. [Medline].
Bassetti M, Repetto E, Mikulska M, Miglino M, Clavio M, Gobbi M, et al. Cryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with alemtuzumab: case report and review of the literature. J Chemother. 2009 Apr. 21(2):211-4. [Medline].
Benson CA, Kaplan JE, Masur H. Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. [Full Text].
Chuck SL, Sande MA. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med. 1989 Sep 21. 321(12):794-9. [Medline].
Day JN, Chau TT, Wolbers M, Mai PP, Dung NT, Mai NH, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013 Apr 4. 368(14):1291-302. [Medline].
Dykstra MA, Friedman L, Murphy JW. Capsule size of Cryptococcus neoformans: control and relationship to virulence. Infect Immun. 1977 Apr. 16(1):129-35. [Medline].
Ellis DH, Pfeiffer TJ. Natural habitat of Cryptococcus neoformans var. gattii. J Clin Microbiol. 1990 Jul. 28(7):1642-4. [Medline].
Eric Searls D, Sico JJ, Bulent Omay S, Bannykh S, Kuohung V, Baehring J. Unusual presentations of nervous system infection by Cryptococcus neoformans. Clin Neurol Neurosurg. 2009 Sep. 111(7):638-42. [Medline].
Friedman GD, Jeffrey Fessel W, Udaltsova NV, Hurley LB. Cryptococcosis: the 1981-2000 epidemic. Mycoses. 2005 Mar. 48(2):122-5. [Medline].
Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis. 2000 Jan. 30(1):47-54. [Medline].
Hayashi Y, Ito G, Takeyama S. [Clinical study on fluconazole (FLCZ) in the treatment of primary pulmonary cryptococcosis]. Kansenshogaku Zasshi. 1998 Dec. 72(12):1261-8. [Medline].
Hoban DJ, Zhanel GG, Karlowsky JA. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients. Antimicrob Agents Chemother. 1999 Jun. 43(6):1463-4. [Medline].
Klepser ME, Wolfe EJ, Pfaller MA. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans. Journal of Antimicrobial Chemotherapy. 1998. 41(3):397-401. [Medline].
Kralovic SM, Rhodes JC. Utility of routine testing of bronchoalveolar lavage fluid for cryptococcal antigen. Journal of Clinical Microbiology. 1998. 36(10):3088-9. [Medline].
Levitz SM. The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis. Rev Infect Dis. 1991 Nov-Dec. 13(6):1163-9. [Medline].
Ma AL, Fong NC, Leung CW. Cryptococcal meningitis in an immunocompetent adolescent. Ann Trop Paediatr. 2008 Sep. 28(3):231-4. [Medline].
Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev. 1995 Oct. 8(4):515-48. [Medline].
National Institute of Allergy and Infectious Diseases, National Institutes of Health. Study Shows Promise of Fluconazole for Treatment of AIDS-Related Cryptococcal Meningitis. Available at: http://www.aegis.com/pubs/Cdc_Fact_Sheets/1993/CDC93043.html. Atlanta, Ga: Centers for Disease Control and Prevention; 1992. [Full Text].
Nielsen K, Cox GM, Wang P, et al. Sexual cycle of Cryptococcus neoformans var. grubii and virulence of congenic a and alpha isolates. Infect Immun. 2003 Sep. 71(9):4831-41. [Medline].
Orsini J, Nowakowski J, Delaney V, Sakoulas G, Wormser GP. Cryptococcal infection presenting as cellulitis in a renal transplant recipient. Transpl Infect Dis. 2009 Feb. 11(1):68-71. [Medline].
Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med. 1992 Mar 19. 326(12):793-8. [Medline].
Robinson PA, Bauer M, Leal MA, et al. Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clinical Infectious Diseases. 1999. 28(1):82-92. [Medline].
[Guideline] Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis. 2000 Apr. 30(4):710-8. [Medline].
Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med. 1992 Jan 9. 326(2):83-9. [Medline].
Selik RM, Chu SY, Ward JW. Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987 to 1992. Ann Intern Med. 1995 Dec 15. 123(12):933-6. [Medline].
[Guideline] Shoham S, Cover C, Donegan N, Fulnecky E, Kumar P. Cryptococcus neoformans meningitis at 2 hospitals in Washington, D.C.: adherence of health care providers to published practice guidelines for the management of cryptococcal disease. Clin Infect Dis. 2005 Feb 1. 40(3):477-9. [Medline].
Singh N, Alexander BD, Lortholary O, Dromer F, Gupta KL, John GT, et al. Cryptococcus neoformans in Organ Transplant recipients: Impact of Calcineurin-Inhibitor Agents on Mortality. Journal of Infectious Diseases. March/2007. 195:756-764. [Medline].
Sundstrom JB, Cherniak R. T-cell-dependent and T-cell-independent mechanisms of tolerance to glucuronoxylomannan of Cryptococcus neoformans serotype A. Infect Immun. 1993 Apr. 61(4):1340-5. [Medline].
Torres HA, Prieto VG, Raad II, Kontoyiannis DP. Proven pulmonary cryptococcosis due to capsule-deficient Cryptococcus neoformans does not differ clinically from proven pulmonary cryptococcosis due to capsule-intact Cr. neoformans. Mycoses. 2005 Jan. 48(1):21-4. [Medline].
van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med. 1997 Jul 3. 337(1):15-21. [Medline].
Voss A, de Pauw BE. High-dose fluconazole therapy in patients with severe fungal infections. Eur J Clin Microbiol Infect Dis. 1999 Mar. 18(3):165-74. [Medline].